RegCell closed a $66 million funding round combining a fully subscribed $44 million Series A and a $22 million non-dilutive grant from Japan’s AMED. The company, focused on an immune tolerance platform built around regulatory T cells, is advancing toward clinical translation of its Treg approach. The investment highlights continued emphasis from both private investors and government programs on cell-based immunomodulation, particularly in areas where durable tolerance could reduce or replace long-term immunosuppression. With the mix of venture capital and non-dilutive funding, RegCell is positioned to deepen preclinical datasets and prepare for the operational and regulatory work needed to move Tregs into human studies.